Safety and tolerability profile of second-line anti-tuberculosis medications (Q38353565)

2 September 2017

1 reference

title

Safety and tolerability profile of second-line anti-tuberculosis medications (English)

1 reference

2 September 2017

1 reference

2

Soumya Swaminathan

1 reference

2 September 2017

Geetha Ramachandran

1

1 reference

2 September 2017

language of work or name

1 reference

1 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

38

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

253-269

1 reference

Synthesis and antibacterial activities of optically active ofloxacin

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

In vitro activity of S-ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

In vitro activity of DR-3355, an optically active ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Quinolones: review of psychiatric and neurological adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Seizures associated with fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Safety profile of the fluoroquinolones: focus on levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Nervous system effects of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Seizures associated with levofloxacin: case presentation and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Convulsions from excessive dosage of nalidixic acid: A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

CONVULSIONS, HYPERGLYCEMIA, AND GLYCOSURIA FROM OVERDOSE OF NALIDIXIC ACID.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Arrhythmias associated with fluoroquinolone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effects of three fluoroquinolones on QT analysis after standard treatment courses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Fluoroquinolones and the risk of serious arrhythmia: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Subclinical hypothyroidism is characterized by increased QT interval dispersion among women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effect of levothyroxine treatment on QT dispersion in patients with subclinical hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Quinolone arthropathy in animals versus children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Safety profile of quinolone antibiotics in the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Fluoroquinolone antibiotics in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Use of quinolones in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Clinical use of fluoroquinolones in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Ciprofloxacin safety in paediatrics: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Fatal hypoglycemia associated with levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Capreomycin-induced serum electrolyte abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hearing loss in patients on treatment for drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hearing loss in children treated for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Community-based therapy for children with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Mechanism of thioamide drug action against tuberculosis and leprosy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. I. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF KANAMYCIN, ETHIONAMIDE AND EITHER CYCLOSERINE OR PYRAZINAMIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Caring for children with drug-resistant tuberculosis: practice-based recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Ethionamide-induced goitrous hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hypothyroidism due to ethionamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Abnormal thyroid function tests in children on ethionamide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Prevalence of hypothyroidism among MDR-TB patients in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Reversible pellagra-like encephalopathy with ethionamide and cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Gynecomastia caused by ethionamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Structure of the Mycobacterium tuberculosis d -Alanine: d -Alanine Ligase, a Target of the Antituberculosis Drug d -Cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Therapeutic drug monitoring in the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Cycloserine-induced encephalopathy: evidence on brain MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Cerebrospinal fluid concentrations of antituberculosis agents in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Iron, mycobacteria and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effect of P.A.S. on the thyroid gland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Radio-iodine measurements of thyroid function during and after P.A.S. treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Goitre and hypothyroidism developing during treatment with P.A.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effect of Para-amino-salicylic Acid on Prothrombin Time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid-induced inhibition of mitochondrial protein synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid: a review of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Safety and tolerability of linezolid in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Hematologic effects of linezolid in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid-associated peripheral and optic neuropathy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid for the treatment of complicated skin and skin structure infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Antimycobacterial activities of riminophenazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Clofazimine enteropathy in a pediatric bone marrow transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

The Treatment of Tuberculosis in Sweden with Para-Aminosalicylic Acid (PAS): A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

The anti-thyroid action of para-aminosalicylic acid

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

21 January 2018

12 December 2020

Fluoroquinolones in paediatrics

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Aminoglycoside Ototoxicity: Influence of Dosage Regimen on Drug Uptake and Correlation between Membrane Binding and some Clinical Features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

Antagonism of the Oxidative Dissimilation of p-Aminobenzoic Acid by p-Aminosalicylic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0267-Y

21 January 2018

1 reference

12 December 2020

Drug-induced hypothyroidism in patients receiving treatment for multidrug-resistant tuberculosis in the UK

1 reference

12 December 2020

Total structure of capreomycin IB, a tuberculostatic peptide antibiotic

1 reference

12 December 2020

Clinical experience with linezolid in infants and children.

1 reference

12 December 2020

Short-course chemotherapy for pulmonary tuberculosis

1 reference

12 December 2020

Experiments on the antituberculous activity of alpha-ethylthioisonicotinamide

1 reference

12 December 2020

Evaluation of a new antituberculous agent. Capreomycin sulfate (capastat sulfate)

1 reference

12 December 2020

Once-daily and twice-daily dosing of p-aminosalicylic acid granules

1 reference

12 December 2020

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

1 reference

12 December 2020

Moxifloxacin-induced arthropathy

1 reference

12 December 2020

Safety and tolerability of linezolid

1 reference

12 December 2020

A case of clofazimine enteropathy

1 reference

12 December 2020

Pharmacokinetics of cycloserine and terizidone. A comparative study

1 reference

12 December 2020

Pseudomembranous colitis in a patient treated with ofloxacin for tuberculosis

1 reference

12 December 2020

Sleep disturbance in children treated with ofloxacin

1 reference

12 December 2020

Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.

1 reference

12 December 2020

Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia

1 reference

12 December 2020

Acute hepatic necrosis associated with ethionamide

1 reference

12 December 2020

1 reference

12 December 2020

Results of resting and ambulatory electrocardiograms in patients with hypothyroidism and after return to euthyroid status

1 reference

12 December 2020

1 reference

12 December 2020

Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction

1 reference

12 December 2020

SEVERE HYPOGLYCEMIC MANIFESTATIONS IN TUBERCULOUS DIABETICS TREATED WITH ETHIONAMIDE

1 reference

12 December 2020

Quantitative estimation of clofazimine in tissue

1 reference

12 December 2020

Para-aminosalicylic acid in the treatment of tuberculosis

1 reference

12 December 2020

Cycloserine and isoniazid in childhood tuberculous infections

1 reference

12 December 2020

1 reference

12 December 2020

Ethionamide-induced hypothyroidism

1 reference

12 December 2020

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity

1 reference

12 December 2020

The mechanism of the goitrogenic action of p-aminosalicylic acid

1 reference

12 December 2020

Side effects of clofazimine therapy

1 reference

12 December 2020

Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin

1 reference

12 December 2020

Acute psychotic reaction probably caused by ethionamide

1 reference

12 December 2020

Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis

1 reference

12 December 2020

1 reference

12 December 2020

Ethionamide-induced gynecomastia

1 reference

12 December 2020

1 reference

12 December 2020

Global challenge of tuberculosis.

1 reference

12 December 2020

A case of myxoedema developing during p-aminosalicylic acid therapy

1 reference

12 December 2020

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

12 December 2020

The use of fluoroquinolones in children

1 reference

12 December 2020

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

1 reference

12 December 2020

1 reference

12 December 2020

The Role of the Cycloserine (Seromycin) Blood Level in the Treatment of Pulmonary Tuberculosis and the Prevention and Control of Cycloserine (Seromycin) Toxicity

1 reference

12 December 2020

Discovery, chemistry, and activity of amikacin

1 reference

12 December 2020

A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association

1 reference

12 December 2020

Mechanism of competitive inhibition of p-aminobenzoic acid oxidation by p-aminosalicylic acid

1 reference

12 December 2020

Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.

1 reference

12 December 2020

Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients.

1 reference

12 December 2020

Treatment with capreomycin, with special reference to toxic effects

1 reference

12 December 2020

Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children

1 reference

12 December 2020

Comparison of the clinical usefulness of ethionamide and prothionamide in initial treatment of tuberculosis: tenth series of controlled trials

1 reference

12 December 2020

Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur)

1 reference

12 December 2020

Mitochondrial rRNA and tRNA and hearing function

1 reference

12 December 2020

Hypersensitivity reactions associated with sodium para-aminosalicylate therapy; four case reports and review of the literature.

1 reference

12 December 2020

The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review

1 reference

12 December 2020

The use of antrenyl in gastro-intestinal irritation due to PAS compounds

1 reference

12 December 2020

Severe arthropathy with ofloxacin in two cases of MDR tuberculosis

1 reference

12 December 2020

Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment

1 reference

12 December 2020

Cycloserine-induced lichenoid drug eruption

1 reference

12 December 2020

Psychotoxic reaction during ethionamide therapy

1 reference

12 December 2020

Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens [Correspondence]

1 reference

12 December 2020

Para-aminosalicylic acid

1 reference

12 December 2020

Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children.

1 reference

12 December 2020

Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis.

1 reference

12 December 2020

1 reference

12 December 2020

Aminoglycosides: nephrotoxicity

1 reference

12 December 2020

[Clinical analysis of protionamide and para-aminosalicylic acid induced hepatotoxicity in 129 cases].

1 reference

12 December 2020

Multidrug-resistant tuberculosis

1 reference

12 December 2020

Ofloxacin-induced seizure

1 reference

12 December 2020

Psychiatric issues in the management of patients with multidrug-resistant tuberculosis.

1 reference

12 December 2020

10.1007/S40264-015-0267-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1013277223

0 references

1 reference